RBC Capital analyst Brian Abrahams raised the firm’s price target on Regeneron to $1,229 from $1,200 and keeps an Outperform rating on the shares. The analyst cites the firm’s surveyed pulmonologists’ excitement around the phase 3 data, the proportion of patients they view as having type 2 inflammation, and the expected rapidity of adoption post-approval. These all suggest that dupixent’s COPD sales potential, along with its contribution to near- and long-term revenue, are likely to be higher than even RBC’s bullish expectations and well above what the Street may be anticipating, the firm tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
- Regeneron, Sanofi announce FDA approved Kevzara for treatment of pJIA
- Biotech Alert: Searches spiking for these stocks today
- Regeneron price target raised to $1,200 from $1,185 at RBC Capital
- FibroGen, Regeneron in deal for oncology assets in evaluation combo study